search
Back to results

Depression and Diabetes Control Trial (DDCT)

Primary Purpose

Diabetes Mellitus, Affective Disorders, Depression

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Diabetes-related affective problems analysis
Goal setting towards improvement of glycaemic control
Diabetes-specific problem-solving therapy
Interventions to increase diabetes treatment motivation
Activation of personal and social resources
Reduction of barriers to self-care/glycaemic control
Cognitive restructuring of diabetes-related problems
Goal definition regarding self-care/glycaemia/well-being
Health care and specific topics (e. g. blood pressure)
Healthy foods, cooking recommendations, recipes
Sports, activities and exercise
Foot care: exercises, care & control, injuries, neuropathy
Diabetes complications
Social aspects of living with diabetes
Sponsored by
Forschungsinstitut der Diabetes Akademie Mergentheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus focused on measuring Diabetes mellitus, Affective disorders, Depressive symptoms, Diabetes distress, Hyperglycaemia, Dysglycaemia, Glycaemic control, Self-care behaviour, Quality of Life, Diabetes acceptance, Diabetes complications, Low-grade inflammation, Inflammatory markers, Stress reactivity, Health-care costs

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age between 18 and 70
  • Diabetes mellitus type 1 or type 2
  • Diabetes duration ≥ 1 year
  • Suboptimal glycaemic control (HbA1c > 7,5%)
  • Elevated depressive symptoms (CES-D score ≥ 16) and/or elevated diabetes distress (PAID score ≥ 40)
  • Sufficient language skills
  • Written informed consent

Exclusion Criteria:

  • Severe major depressive disorder according to ICD-10
  • Current psychiatric and/or psychotherapeutic treatment
  • Current antidepressive medical treatment
  • Suicidal ideation
  • Acute mental disorder of the following type: schizophrenia or other psychotic disorder, bipolar disorder, severe eating disorder (anorexia nervosa, bulimia nervosa), substance use disorder
  • History of personality disorder
  • Severe somatic illnesses: dialysis-dependent nephropathy, acute cancer, severe heart disease (NYHA III - IV), severe neurologic illness (e. g. MS, dementia), severe autoimmune disease
  • Terminal illness
  • Bedriddenness
  • Guardianship

Sites / Locations

  • Forschungsinstitut der Diabetes Akademie Mergentheim e. V.
  • Diabetes Center Mergentheim

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Cognitive-behavioural group treatment

Treatment-as-usual

Arm Description

Five group sessions of diabetes-Specific cognitive-behavioural group treatment for diabetes patients with depressive symptoms and/or diabetes distress and suboptimal glycaemic control. Interventions: Diabetes-related affective problems analysis Goal setting towards improvement of glycaemic control Diabetes-specific problem-solving therapy Interventions to increase diabetes treatment motivation Activation of personal and social resources Reduction of barriers to self-care/glycaemic control Cognitive restructuring of diabetes-related problems Goal definition regarding self-care/glycaemia/well-being

Standard diabetes education. Interventions: Health care and specific topics (e. g. blood pressure) Healthy foods, cooking recommendations, recipes Sports, activities and exercise Foot care: exercises, care & control, injuries, neuropathy Diabetes complications Social aspects of living with diabetes

Outcomes

Primary Outcome Measures

Improvement of glycaemic control as measured by the HbA1c
Mean difference between HbA1c values at baseline and at 12 month follow

Secondary Outcome Measures

Improvement of glycaemic control as measured by participants' blood glucose meter or glucose monitoring devices (data are extracted from tools using the diasend application)
Mean difference between average glucose test scores during an 8-week period before baseline and those during an 8-week period before 12 month follow
Improvement of depressive symptoms as measured with the Center for Epidemiologic Studies Depression Scale (CES-D)
Mean difference between CES-D scores at baseline and at 12 month follow up
Improvement of depressive symptoms as measured with the Patient Health Questionnaire Module for Depression (PHQ-9)
Mean difference between PHQ-9 scores at baseline and at 12 month follow up
IImprovement of diabetes distress as measured with the Problem Areas in Diabetes Scale (PAID)
Mean difference between PAID scores at baseline and at 12 month follow
IImprovement of diabetes distress as measured with the Diabetes Distress Scale (DDS)
Mean difference between DDS scores at baseline and at 12 month follow
Improvement of self-care behaviour as measured with the Summary of Diabetes Self-Care Activities Measure (SDSCA)
Mean difference between SDSCA scores at baseline and at 12 month follow
Improvement of self-care behaviour as measured with the Diabetes Self-Management Questionnaire (DSMQ)
Mean difference between DSMQ scores at baseline and at 12 month follow
Improvement of diabetes acceptance as measured with the Diabetes Acceptance Scale (DAS)
Mean difference between DAS scores at baseline and at 12 month follow
Improvement of quality of life as measured with the EuroQol Five-Dimensions Questionnaire (EQ-5D)
Mean difference between EQ-5D scores at baseline and at 12 month follow
Improvement of quality of life as measured with the Short Form-36 Health Survey (SF-36)
Mean difference between SF-36 scores at baseline and at 12 month follow

Full Information

First Posted
February 2, 2016
Last Updated
August 27, 2018
Sponsor
Forschungsinstitut der Diabetes Akademie Mergentheim
Collaborators
German Center for Diabetes Research, Helmholtz Zentrum München, German Diabetes Center, German Federal Ministry of Education and Research
search

1. Study Identification

Unique Protocol Identification Number
NCT02675257
Brief Title
Depression and Diabetes Control Trial
Acronym
DDCT
Official Title
Depression and Diabetes Control Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
July 1, 2015 (Actual)
Primary Completion Date
March 31, 2018 (Actual)
Study Completion Date
June 30, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Forschungsinstitut der Diabetes Akademie Mergentheim
Collaborators
German Center for Diabetes Research, Helmholtz Zentrum München, German Diabetes Center, German Federal Ministry of Education and Research

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This randomised controlled trial evaluates a cognitive-behavioural intervention for diabetes patients with suboptimal glycaemic control and comorbid depressive symptoms and/or diabetes distress. The main outcome is the improvement of suboptimal glycaemic control (HbA1c). Secondary outcomes are effects on depressive symptoms, diabetes distress, self-care behaviour, diabetes acceptance and quality of life. The treatment group will be treated with a cognitive-behavioural group treatment comprising specific interventions to improve glycaemic control and reduce diabetes distress as well as depressive symptoms. The control group will receive treatment-as-usual. A total of 212 study participants will be included. A secondary study objective is to analyse associations of suboptimal glycaemic control, depressive symptoms and diabetes distress with inflammatory markers.
Detailed Description
Suboptimal glycaemic control is an established risk factor for the development of serious long-term complications of diabetes. Moreover, it is associated with elevated risks of significant hyperglycaemic acute events such as hyperosmolar hyperglycemic state or diabetic ketoacidosis. Hence, patients with diabetes and persistent suboptimal glycaemic control are at higher risk of having a rather poor prognosis. Besides physiological and medical factors, psychological problems have been found to predict suboptimal glycaemic control. A number of studies found depressive symptoms to be independently associated with hyperglycaemia. Others focussed on diabetes-specific affective problems - the so called diabetes distress - and suggested this factor to be of great importance. Finally, some studies found that depressive symptoms and diabetes distress may interact, with the coocurrence of these factors being associated with the highest risk or suboptimal glycaemic control. The results correspond to other findings suggesting that both depressive symptoms and diabetes distress are often associated with reduced diabetes self-care, which can explain the associations of those factors with hyperglycaemia. On the other hand, suboptimal glycaemic control could also be an explanation for affective problems - either mediated by physiological mechanisms or psychological ones, e.g. dissatisfaction or guilt. Hence, it is valid to assume that the link between depressive symptoms and/or diabetes distress may be bidirectional - although evidence to support this assumption is missing. Following this evidence and background, the investigators designed the a to analyse the relationships between suboptimal glycaemic control, depressive symptoms and diabetes distress in diabetes using a prospective study design. The study is a randomized trial in which a cognitive-behavioural group treatment is compared to a treatment-as-usual condition (standard diabetes education) regarding their efficacy in improving suboptimal glycaemic control. 212 diabetes patients with suboptimal glycaemic control (HbA1c value > 7.5%) and elevated depressive symptoms (Center for Epidemiologic Studies Depressions Scale score ≥ 16) and/or elevated diabetes distress (Problem Areas In Diabetes Scale score ≥ 40) will be randomly assigned to either the treatment group or treatment-as-usual. The primary outcome is the improvement of suboptimal glycaemic control (reduction of HbA1c) in the 12-month follow-up. As secondary outcomes positive baseline-to-follow up changes regarding depressive symptoms, diabetes distress, diabetes self-care behaviour, diabetes acceptance and quality of life are assessed. A second study objective is to analyse cross-sectional and prospective associations of suboptimal glycaemic control, depressive symptoms and diabetes distress with serum levels of the following inflammatory markers: hsCRP, IL-6, IL-18, IL-1Ra, MCP-1 and Adiponectin. Potential effects of the treatment groups on these markers will also be examined.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Affective Disorders, Depression, Depressive Symptoms, Emotional Distress, Diabetes Complications
Keywords
Diabetes mellitus, Affective disorders, Depressive symptoms, Diabetes distress, Hyperglycaemia, Dysglycaemia, Glycaemic control, Self-care behaviour, Quality of Life, Diabetes acceptance, Diabetes complications, Low-grade inflammation, Inflammatory markers, Stress reactivity, Health-care costs

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
213 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cognitive-behavioural group treatment
Arm Type
Experimental
Arm Description
Five group sessions of diabetes-Specific cognitive-behavioural group treatment for diabetes patients with depressive symptoms and/or diabetes distress and suboptimal glycaemic control. Interventions: Diabetes-related affective problems analysis Goal setting towards improvement of glycaemic control Diabetes-specific problem-solving therapy Interventions to increase diabetes treatment motivation Activation of personal and social resources Reduction of barriers to self-care/glycaemic control Cognitive restructuring of diabetes-related problems Goal definition regarding self-care/glycaemia/well-being
Arm Title
Treatment-as-usual
Arm Type
Active Comparator
Arm Description
Standard diabetes education. Interventions: Health care and specific topics (e. g. blood pressure) Healthy foods, cooking recommendations, recipes Sports, activities and exercise Foot care: exercises, care & control, injuries, neuropathy Diabetes complications Social aspects of living with diabetes
Intervention Type
Behavioral
Intervention Name(s)
Diabetes-related affective problems analysis
Intervention Description
Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
Intervention Type
Behavioral
Intervention Name(s)
Goal setting towards improvement of glycaemic control
Intervention Description
Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
Intervention Type
Behavioral
Intervention Name(s)
Diabetes-specific problem-solving therapy
Intervention Description
Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
Intervention Type
Behavioral
Intervention Name(s)
Interventions to increase diabetes treatment motivation
Intervention Description
Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
Intervention Type
Behavioral
Intervention Name(s)
Activation of personal and social resources
Intervention Description
Activation of personal and social resources with a view to diabetes control and affective problems
Intervention Type
Behavioral
Intervention Name(s)
Reduction of barriers to self-care/glycaemic control
Intervention Description
Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
Intervention Type
Behavioral
Intervention Name(s)
Cognitive restructuring of diabetes-related problems
Intervention Description
Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
Intervention Type
Behavioral
Intervention Name(s)
Goal definition regarding self-care/glycaemia/well-being
Intervention Description
Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
Intervention Type
Behavioral
Intervention Name(s)
Health care and specific topics (e. g. blood pressure)
Intervention Description
Education on health care and specific topics (e. g. blood pressure)
Intervention Type
Behavioral
Intervention Name(s)
Healthy foods, cooking recommendations, recipes
Intervention Description
Education on healthy and unhealthy foods, cooking and recipes
Intervention Type
Behavioral
Intervention Name(s)
Sports, activities and exercise
Intervention Description
Education on sports, activities and exercise
Intervention Type
Behavioral
Intervention Name(s)
Foot care: exercises, care & control, injuries, neuropathy
Intervention Description
Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
Intervention Type
Behavioral
Intervention Name(s)
Diabetes complications
Intervention Description
Education on diabetes complications
Intervention Type
Behavioral
Intervention Name(s)
Social aspects of living with diabetes
Intervention Description
Education on social aspects of living with diabetes
Primary Outcome Measure Information:
Title
Improvement of glycaemic control as measured by the HbA1c
Description
Mean difference between HbA1c values at baseline and at 12 month follow
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Improvement of glycaemic control as measured by participants' blood glucose meter or glucose monitoring devices (data are extracted from tools using the diasend application)
Description
Mean difference between average glucose test scores during an 8-week period before baseline and those during an 8-week period before 12 month follow
Time Frame
12 months
Title
Improvement of depressive symptoms as measured with the Center for Epidemiologic Studies Depression Scale (CES-D)
Description
Mean difference between CES-D scores at baseline and at 12 month follow up
Time Frame
12 months
Title
Improvement of depressive symptoms as measured with the Patient Health Questionnaire Module for Depression (PHQ-9)
Description
Mean difference between PHQ-9 scores at baseline and at 12 month follow up
Time Frame
12 months
Title
IImprovement of diabetes distress as measured with the Problem Areas in Diabetes Scale (PAID)
Description
Mean difference between PAID scores at baseline and at 12 month follow
Time Frame
12 months
Title
IImprovement of diabetes distress as measured with the Diabetes Distress Scale (DDS)
Description
Mean difference between DDS scores at baseline and at 12 month follow
Time Frame
12 months
Title
Improvement of self-care behaviour as measured with the Summary of Diabetes Self-Care Activities Measure (SDSCA)
Description
Mean difference between SDSCA scores at baseline and at 12 month follow
Time Frame
12 months
Title
Improvement of self-care behaviour as measured with the Diabetes Self-Management Questionnaire (DSMQ)
Description
Mean difference between DSMQ scores at baseline and at 12 month follow
Time Frame
12 months
Title
Improvement of diabetes acceptance as measured with the Diabetes Acceptance Scale (DAS)
Description
Mean difference between DAS scores at baseline and at 12 month follow
Time Frame
12 months
Title
Improvement of quality of life as measured with the EuroQol Five-Dimensions Questionnaire (EQ-5D)
Description
Mean difference between EQ-5D scores at baseline and at 12 month follow
Time Frame
12 months
Title
Improvement of quality of life as measured with the Short Form-36 Health Survey (SF-36)
Description
Mean difference between SF-36 scores at baseline and at 12 month follow
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
Inflammatory Marker: hsCRP
Description
Mean difference between hsCRP scores at baseline and at 12 month follow
Time Frame
12 months
Title
Inflammatory Marker: IL-6
Description
Mean difference between IL-6 scores at baseline and at 12 month follow
Time Frame
12 months
Title
Inflammatory Marker: IL-18
Description
Mean difference between IL-18 scores at baseline and at 12 month follow
Time Frame
12 months
Title
Inflammatory Marker: IL-1Ra
Description
Mean difference between IL-1Ra scores at baseline and at 12 month follow
Time Frame
12 months
Title
Inflammatory Marker: MCP-1
Description
Mean difference between MCP-1 scores at baseline and at 12 month follow
Time Frame
12 months
Title
Inflammatory Marker: Adiponectin
Description
Mean difference between Adiponectin scores at baseline and at 12 month follow
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 18 and 70 Diabetes mellitus type 1 or type 2 Diabetes duration ≥ 1 year Suboptimal glycaemic control (HbA1c > 7,5%) Elevated depressive symptoms (CES-D score ≥ 16) and/or elevated diabetes distress (PAID score ≥ 40) Sufficient language skills Written informed consent Exclusion Criteria: Severe major depressive disorder according to ICD-10 Current psychiatric and/or psychotherapeutic treatment Current antidepressive medical treatment Suicidal ideation Acute mental disorder of the following type: schizophrenia or other psychotic disorder, bipolar disorder, severe eating disorder (anorexia nervosa, bulimia nervosa), substance use disorder History of personality disorder Severe somatic illnesses: dialysis-dependent nephropathy, acute cancer, severe heart disease (NYHA III - IV), severe neurologic illness (e. g. MS, dementia), severe autoimmune disease Terminal illness Bedriddenness Guardianship
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Haak, Prof., MD
Organizational Affiliation
Diabetes Center Mergentheim
Official's Role
Principal Investigator
Facility Information:
Facility Name
Forschungsinstitut der Diabetes Akademie Mergentheim e. V.
City
Bad Mergentheim
State/Province
Baden-Württemberg
ZIP/Postal Code
97980
Country
Germany
Facility Name
Diabetes Center Mergentheim
City
Bad Mergentheim
State/Province
BW
ZIP/Postal Code
97980
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Depression and Diabetes Control Trial

We'll reach out to this number within 24 hrs